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Dear Sirs,
Peripheral neuropathy is an important complication of
diabetes mellitus. A particular type of proximal dia-
betic neuropathy, lumbosacral radiculoplexus neuropathy
(DLSRPN), presents with pelvi-femoral pain followed by
weakness, beginning focally in the upper leg or thigh with
spreadtothecontralaterallimb,andvariable weightloss[1].
Ischemicnerveinjuryduetomicroscopicvasculitishasbeen
a widely postulated unifying hypothesis of DLSRPN and
derived from one well studied postmortem case reported
4 decades ago, the ﬁnding of microscopic vasculitis in
proximal or distal cutaneous nerve biopsy tissue and the
favorable response to immunotherapy.
A 59 year old man with diabetes mellitus for 15 years
treated with oral hypoglycemic medication noted left thigh
pain, paresthesia, and impotence commencing in January
1995. This was followed by sensory changes and weakness
ﬁrst in the left leg then in the other in a stepwise fashion
leading ﬁrst to the necessity of a cane, then walker
accompanied by a 15 lb weight loss, until he was essen-
tially bed-bound and admitted to the hospital in June 1995.
Admission neurological examination showed wasting and
near-ﬂail weakness in the legs from the thighs to the toes
with rare limb fasciculation, mild distal weakness of the
hands in the distribution of the distal median and ulnar
nerves, mild stocking sensory loss to light touch, vibratory
and cold temperature stimulation to just above the knee,
areﬂexia, and otherwise intact cranial nerves and cognition.
Admission laboratory studies showed erythrocyte sedi-
mentation rate 60 mm/hour (normal \20), fasting blood
glucose 250 mg/dL (normal \105), and hemoglobin A1C
level 7.1% (normal\6). Causes of neuropathy other than
diabetes mellitus were excluded by appropriate investiga-
tions. Nerve conduction studies and electromyography
(EMG) of the right arm and leg showed axonal neuropathy
with acute and chronic denervation in proximal and distal
limb muscles including lumbosacral paraspinal muscles.
Cerebrospinal ﬂuid showed total protein 122 mg/dL (nor-
mal\45) and glucose 88 mg/dL with 12 white blood cells/
mm
3 (normal \5). Right sural nerve biopsy showed fea-
tures of microvasculitis (MV). Inﬂammatory cells sur-
rounded a small epineurial artery with extension into the
vascular wall, with reactive luminal connective tissue
suggesting recanalization of a thrombus. An adjacent nerve
fascicle showed marked loss of myelinated nerve ﬁbers.
The patient was treated for painful diabetic lumbosacral
plexopathy and peripheral nerve vasculitis according to
prevailing standards with 2 g/kg intravenous immuno-
globulin for 5 days, followed by 750 mg of intravenous
cyclophosphamide and 1,000 mg of methylprednisolone
intravenously for 3 additional days. This was followed by
acute tubular necrosis, increasing lethargy, unresponsive-
ness, and aspiration pneumonia requiring mechanical
ventilation. He expired 4 weeks after admission.
General autopsy showed no evidence of systemic or
peripheral nerve vasculitis. The brain showed diffuse loss of
neurons in all sampled cortical areas, including the cere-
bellum, consistent with anoxia secondary to cardiac arrest.
Sections of extradural lumbar plexus, sciatic, and femoral
nerve tissue showed perivascular epineurial inﬂammation
with inﬁltration of adjacent endoneurium (Fig. 1a, b).
Perivascular inﬂammation, not MV, was noted in
postmortem nerve tissue in our patient. Although the
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suggest the contribution of vascular autoimmune factors in
the etiopathogenesis of DLSRPN, but do not provide clear
evidence of ischemic nerve injury due to microscopic
vasculitis in this disorder.
The history of DLSRPN embodies more than a century
of insights into proximal diabetic neuropathy (PDN), dia-
betic amyotrophy, and peripheral nerve vasculitis. An
ischemic etiopathogenesis of DLSRPN was ﬁrst suggested
by Raff and colleagues [2] in a newly diagnosed non-
insulin dependent diabetic with mononeuritis multiplex
presenting with acute asymmetrical leg pain and weakness,
bilateral distal sensory disturbances, and reduced leg
reﬂexes. Postmortem examination showed a multitude of
unilateral small ischemic infarctive lesions of the proximal
major nerve trunks of the leg and lumbosacral plexus.
Further proof of the ischemic inﬂammatory basis of
DLSRPN stemmed from analysis of proximal and distal
cutaneous nerve biopsy. In 1984, Bradley and coworkers [3]
delineated the syndrome of painful lumbosacral plexopathy
with elevated erythrocyte sedimentation rate among six
patients, three of whom were diabetic including one newly
diagnosed, with perivasculitis (PV) in sural nerve biopsies.
In the same period, Johnson and coworkers [4] noted focal
fascicular lesions distributed in proximal lumbosacral
plexus trunks of 18/32 samples obtained at autopsy from
diabeticpatients,aquarterofwhomwereinsulin-dependent,
without mononeuritis multiplex employing epoxy-embed-
ded and teased nerve ﬁber sections. These ﬁndings suggest a
possible propensity for the spontaneous evolution of
DLSRPN in patients with diabetic neuropathy. A decade
later, Said and coworkers [5] studied 10 non-insulin
dependent diabetics with painful PDN and reported ische-
mic nerve lesions due to arteritis in three biopsies of the
intermedius cutaneous nerve of the thigh, and four others
withisolatedmononuclearcellinﬂammation.Oneyearlater,
Krendel and associates [6] identiﬁed 5 of 15 non-insulin
dependent diabetics with progressive proximal asymmetric
neuropathy progressing over 1–15 months punctuated by
pain, weakness, and atrophy of one thigh, followed by
involvement of the contralateral extremity in 2–10 weeks.
Biopsy of the cutaneous branch of the femoral nerve in one
patient showed epineurial PV, while sural nerve tissue in
another had microfasciculation that was postulated to result
from regeneration after nerve infarction. In 1996, Younger
and colleagues [7] characterized the vascular endoneurial
and epineurial inﬂammatory lesions among 12 patients with
stepwise or slowly progressive proximal weakness, wasting,
and pain, and axonopathy on electrodiagnostic studies
indicative of DLSRPN. Six nerves showed epineurial MV
andsixhadepineurialPVcomprisedofcytotoxic/suppressor
T cells with activated endoneurial lymphocytes that
expressed immunoreactive cytokines, major histocompati-
bility class II antigens, endoneurial and epineurial C3d and
C5b-9 complement. The nerve tissue of two patients with
MV in addition had focal pathology indicative of ischemia.
In 1998, Llewelyn and colleagues [8] studied 15 patients
including one with insulin-dependent diabetes and PDN
manifested by subacute asymmetric pain, weakness, and
wasting of the legs. Epineurial MV was noted in three of 15
femoral intermedius cutaneous nerve biopsies comprised of
helper T cells and cytotoxic/suppressor T and B cells, with a
single occluded vessels in two, and T cell MV in the sural
nerve and vastus lateralis muscle of the another patient.
Dyck and colleagues [9] later reported perivascular
inﬂammation in all 33 distal cutaneous nerves in DLSRPN,
15 (45%) of which inﬁltrated the vessel wall, and MV in
two nerves with histological features of ischemic nerve
injury. One year later, Kelkar and colleagues [10]
Fig. 1 Postmortem histopathology. a Transverse section of the left
sciatic nerve shows perivascular chronic inﬂammation surrounding
small blood vessels of the epineurium. b Transverse section of the left
femoral nerve in addition shows perivascular chronic inﬂammation in
the subperineurial area. Inﬂammatory cells inﬁltrate the adjacent
endoneurium (Parafﬁn, H&E, 200X)
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spontaneous activity in two proximal leg muscles inner-
vated by different nerves, including but not limited to
paraspinal muscles indicative of DLSRPN; all were non-
insulin dependent, with functional impairment that varied
from three patients who were wheelchair bound, four
necessitating a walker, and eight patients requiring support
of a cane to ambulate at presentation. Fourteen patients
underwent femoral cutaneous nerve biopsy and two
underwent sural nerve biopsy. Nerve biopsy pathology
showed epineurial MV comprised of polymorphonuclear
cells in postcapillary venules of the femoral cutaneous
nerve in four patients, and lymphocytic MV of the sural
nerve of six patients, including one nerve with occlusion
and recanalization of an epineurial vessel. There was
binding of immunoreactive IgM and activated complement
protein in the subperineurial space and endoneurium con-
sistent with immune-mediated ischemic injury.
The past 3 decades have witnessed a critical appraisal of
the immunotherapeutic management of DLSRPN. Bradley
and coworkers [3] administered corticosteroids ranging
from 60 mg daily to 80 mg of alternate day prednisone
alone in one patient, and in association with cyclophos-
phamide 100 mg daily in two others, with improvement
over 6 weeks often with a decrease in the erythrocyte
sedimentation rate. A decade later the same authors [11]
treated the disorder with 2 g/kg body weight of intravenous
immune globulin (IVIg) over 5 days followed by single
monthly treatments for 3 months, the endpoint of which
was improved Medical Research Council (MRC) graded
strength that enabled ambulation. In the same year, 1995,
Said and colleagues [5] treated two of 10 affected patients
with prednisone 1 mg/kg/day for 6 weeks prompted by the
presence of lymphocytic vasculitis in epineurial blood
vessels with asymmetrical nerve lesions and centrofasci-
cular axonal loss along the intermedius nerve of the thigh
in one, and another with occlusion of a perineurial blood
vessel and a small mononuclear inﬂammatory cell inﬁltrate
along the superﬁcial sensory branch of the peroneal nerve.
Both patients had improved pain along with corticosteroid
induced hyperglycemia, including one patient with a gas-
tric ulcer. Seven additional patients, all without vasculitis
improved spontaneously. Krendel and coworkers [6] trea-
ted ﬁve affected patients with IVIg alone in one patient, in
combination with 60 mg of prednisone in 3 patients, or
with 1 g of intravenous cyclophosphamide in another. All
ﬁve patients stopped progressing after commencing therapy
and gained at least 1 grade of the MRC scale.
Most recently, Dyck and colleagues [9, 12] noted
equally signiﬁcant objective improvement in primary out-
come measures of 49 patients with DLSRPN randomized to
1 g 3 times weekly of intravenous methylprednisolone for
12 weeks, compared to 26 patients with DLSRPN who
received placebo when analyzed at 52 [12] and 104 weeks
[9]. However, the methylprednisolone treated patients
reported a greater degree of symptom improvement as
judged by changes in a neuropathy symptom change sub-
score for pain. A randomized, double-blind placebo-con-
trolled trial of IVIg on recovery time of patients with PDN
and EMG evidence of proximal lower limb plexus or
radicular denervation that commenced in 1999 [13] is still
ongoing but no longer recruiting study participants, and has
yet to publish its ﬁndings.
In summary, DLSRPN is a well recognized, painful,
asymmetrical, immune mediated neuropathy of the lower
limbs associated generally with non-insulin dependent dia-
betes, weight loss, and signiﬁcant morbidity. The disorder
has evolved along different nomenclature and eponymic
terminology reﬂecting the diversity in opinions concerning
the anatomic localization and underlying etiopathogenesis.
The clinicopathological ﬁndings in the present patient were
consistent with a mechanismof ischemic nerve injury dueto
microscopic vasculitis. Neurologists faced with the chal-
lenge of treating DLSRPN must choose from among avail-
able immune mediated interventions, weighing the inherent
risks, beneﬁts, and anticipated efﬁcacy, and tailored to the
clinical, electrophysiological, and cutaneous nerve biopsy
ﬁndings to optimize recovery and forestall severe neuro-
logical disability.
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